Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma.
- Resource Type
- Academic Journal
- Authors
- Hassani M; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Department of Respiratory Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Tak T; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Department of Respiratory Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; van Aalst C; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Department of Respiratory Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; van Nederveen S; Department of Respiratory Medicine, HAGA Hospital, 2545AA The Hague, The Netherlands.; Tesselaar K; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Vrisekoop N; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Department of Respiratory Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Koenderman L; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.; Department of Respiratory Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.
- Source
- Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
- Subject
- Language
- English
Mepolizumab (anti-IL-5) is a successful biological for treatment of T2/eosinophilic asthma by blocking the IL-5-eosinophil axis. The kinetics of human eosinophils in blood and sputum was determined to better understand the underlying mechanism(s). Pulse-chase labeling was performed with 6,6- 2 H 2 -glucose in patients with asthma after short term (4 days) and long term (84 days) treatment with mepolizumab (n = 10) or placebo (n = 10). The retention time of eosinophils in sputum was longer than in blood. Treatment with mepolizumab induced a fast and long-lasting eosinopenia with no reduction of eosinophil progenitors. The retention time of eosinophils in blood was delayed only after short-term treatment. This leads to the hypothesis that IL-5 increases the number of IL-5-responsive progenitors and potentiates homing to the tissues, leading to reactive eosinophilia. Long-term treatment is associated with low numbers of IL-5-independent eosinophils in blood and tissues. Therefore, long-term treatment with mepolizumab restores the kinetics of eosinophils as normally found in homeostasis.
Competing Interests: The authors declare no competing interests.
(© 2021 The Author(s).)